Mark S. Forman - Dec 31, 2023 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role
Chief Medical Officer
Signature
/s/ Edgar Cale, Attorney-in-Fact
Stock symbol
PASG
Transactions as of
Dec 31, 2023
Transactions value $
-$14,390
Form type
4
Date filed
1/3/2024, 04:21 PM
Previous filing
Apr 5, 2023
Next filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PASG Common Stock Options Exercise +50K +451.18% 61.1K Dec 31, 2023 Direct F1, F2
transaction PASG Common Stock Sale -$14.4K -15.8K -25.89% $0.91 45.3K Jan 2, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PASG Restricted Stock Unit Options Exercise $0 -50K -100% $0.00* 0 Dec 31, 2023 Common Stock 50K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.
F3 The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F4 Each RSU represents a contingent right to receive one share of Issuer's common stock.
F5 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.